Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (Weighted Average) (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $66.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 2280.93% to $66.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $66.8 million through Dec 2025, up 2280.93% year-over-year, with the annual reading at $66.8 million for FY2025, 2280.93% up from the prior year.
  • Shares Outstanding (Weighted Average) hit $66.8 million in Q4 2025 for Cardiff Oncology, up from $1.1 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $66.8 million in Q4 2025 to a low of $1.1 million in Q3 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $26.5 million across 5 years, with a median of $20.8 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): crashed 93.72% in 2024 and later skyrocketed 2280.93% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $4.5 million in 2021, then dropped by 2.88% to $4.4 million in 2022, then crashed by 35.61% to $2.8 million in 2023, then dropped by 0.02% to $2.8 million in 2024, then surged by 2280.93% to $66.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CRDF at $66.8 million in Q4 2025, $1.1 million in Q3 2025, and $66.5 million in Q2 2025.